4
Changes in Ownership
MoonLake Immunotherapeutics Filed Acc 0001213900-23-028293
Chief Scientific Officer acquired 598,096 shares (conversion)
- Chief Scientific Officer returned 598,096 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Reich Kristian Chief Scientific Officer | 2023-04-05 | Conversion | +500,006 | 500,006 | I | ||
| Reich Kristian Chief Scientific Officer | 2023-04-05 | Returned to the company | −500,006 | 2,527,477 | I | ||
| Reich Kristian Chief Scientific Officer | 2023-04-05 | Conversion | +98,090 | 98,090 | D | ||
| Reich Kristian Chief Scientific Officer | 2023-04-05 | Returned to the company | −98,090 | 238,297 | D | ||
| Derivatives | |||||||
| Reich Kristian Chief Scientific Officer | 2023-04-05 | Conversion · Common shares, par value CHF 0.10 per share, of MoonLake AG | −14,864 | 75,136 | I | ||
| Reich Kristian Chief Scientific Officer | 2023-04-05 | Conversion · Common shares, par value CHF 0.10 per share, of MoonLake AG | −2,916 | 7,084 | D | ||
Loading xslF345X04/ownership.xml…